ISHL12 Abstracts

Early Stages

136: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
Authors:
- Dennis A. Eichenauer
- Ina Bühnen
- Michael Fuchs
- Richard Greil
- Alden Moccia
- Josée M. Zijlstra
- Sylvia Hartmann
- Carsten Kobe
- Markus Dietlein
- Andreas Engert
- Peter Borchmann
View full abstract at Hemasphere…
Abstract Talk in “Early Stages”
124: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
Authors:
- Andrea Gallamini
- Marco Picardi
- Kateryna Filonenko
- Manuel Gotti
- Javier Núñez Céspedes
- Andrea Rossi
- Eva Domingo-Domènech
- Agnieszka Giza
- Roberto Sorasio
- Livio Trentin
- Mariana Bastos Oteiro
- Ewa Paszkiewicz-Kozik
- Ramon García Sanz
- Caterina Patti
- Stephane Chauvie
- Fabrizio Bergesio
- Luca Guerra
- Alessandro Rambaldi
- Ana Sureda Balari
- Jan Maciej Zaucha
View full abstract at Hemasphere…
Abstract Talk in “Early Stages”
63: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
Authors:
- Rebecca Shakir
- Catriona Gilmour-Hamilton
- Craig Bakin
- Isabelle Gent
- Adam Holloway
- Alison Meeson
- Johanna Ramroth
- Georgios Ntentas
- David Cutter
- Michele Peters
View full abstract at Hemasphere…
Abstract Talk in “Early Stages”
104: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
Authors:
- Heidi Mocikova
- Jana Markova
- Lubica Gaherova
- Maria Maco
- Alice Sýkorová
- David Belada
- Marie Lukášová
- Vit Prochazka
- Juraj Duras
- Tomas Kozak
View full abstract at Hemasphere…
142: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
Authors:
- Lutz van Heek
- Colin Stuka
- Helen Kaul
- Horst Müller
- Jasmin Mettler
- Felicitas Hitz
- Christian Baues
- Michael Fuchs
- Peter Borchmann
- Andreas Engert
- Markus Dietlein
- Conrad-Amadeus Voltin
- Carsten Kobe
View full abstract at Hemasphere…
150: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma.
Authors:
- John Radford
- Toyin Adedayo
- Arzhang Ardavan
- Sally F. Barrington
- Leanne Berkahn
- Stephane Chauvie
- Laura Clifton-Hadley
- Graham P. Collins
- Michael Crump
- David Cutter
- Darren Edwards
- Martin Hutchings
- Tim Illidge
- Amy A. Kirkwood
- Kim Linton
- Craig H. Moskowitz
- Pip Patrick
- Beth Phillips
- Lois Shepherd
- Sanne Tonino
- Judith Trotman
- Joanna Williams
- Nicole Wong Doo
View full abstract at Hemasphere…

Living beyond Lymphoma

169: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
Authors:
- Suzanne I.M. Neppelenbroek
- Yvonne M.G. Geurts
- Berthe M. P. Aleman
- Cécile P.M. Janus
- Pieternella J. Lugtenburg
- Saskia E. Rademaker
- Roel J. de Weijer
- Maaike G.A. Schippers
- Bastiaan D.P. Ta
- Wouter J. Plattel
- Josée M. Zijlstra
- Richard W.M. van der Maazen
- Marten R. Nijziel
- Francisca Ong
- Erik C. Schimmel
- Eduardus F.M. Posthuma
- Marie José Kersten
- Lara H. Böhmer
- Karin Muller
- Harry R. Koene
- Liane C.J. te Boome
- Yavuz M. Bilgin
- Eva de Jongh
- Flora E. van Leeuwen
- Michael Schaapveld
View full abstract at Hemasphere…
Abstract Talk in “Living beyond Lymphoma”
58: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
Authors:
- Joshua P. Entrop
- Caroline E. Weibull
- Karin E. Smedby
- Lasse Hjort Jakobsen
- Andreas K. Øvlisen
- Daniel Molin
- Ingrid Glimelius
- Anna Marklund
- Harald Holte
- Alexander Fosså
- Knut B. Smeland
- Tarec Christoffer El-Galaly
- Sandra Eloranta
View full abstract at Hemasphere…
Abstract Talk in “Living beyond Lymphoma”
182: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.
Authors:
- Michaela Dinan
- Kayla Stratton
- Wendy Leisenring
- Yutaka Yasui
- Eric Chow
- Emily Tonorezos
- Chaya Moskowitz
- Jennifer Yeh
- David Noyd
- Gregory Armstrong
- Kevin Oeffinger
View full abstract at Hemasphere…
Abstract Talk in “Living beyond Lymphoma”
133: A pilot of lung cancer screening for survivors of Hodgkin lymphoma
Authors:
- Rachel Broadbent
- Philip Crosbie
- John Radford
- Christopher J. Armitage
- Ben Taylor
- Joseph Mercer
- Sean Tenant
- Kim Linton
View full abstract at Hemasphere…
157: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
Authors:
- Jana Marková
- Heidi Mociková
- Lubica Gaherová
- Katerina Klásková
- Maria Maco
- Katerina Dedeckova
- Tomas Kozak
View full abstract at Hemasphere…
95: Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients
Authors:
- Chloé Chuzel
- Virginie Simon
- Hélène Béhal
- Franck Morschhauser
- Christine Decanter
- Morgane Nudel
View full abstract at Hemasphere…
81: Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?
Authors:
- Annelies Nijdam
- Eline M.J. Lammers
- Berthe M. P. Aleman
- Josée M. Zijlstra
- Flora E. van Leeuwen
- on behalf of the BETER consortium
View full abstract at Hemasphere…
100: First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands
Authors:
- Eline M.J. Lammers
- Annelies Nijdam
- Josée M. Zijlstra
- Cécile P.M. Janus
- Roel J. de Weijer
- Flora E. van Leeuwen
- Berthe M. P. Aleman
- on behalf of the BETER consortium
View full abstract at Hemasphere…
130: Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma
Authors:
- Cherie Bates
- Funmi Bamigbola
- Lorna Warwick
View full abstract at Hemasphere…
107: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
Authors:
- Yvonne M.G. Geurts
- Rebecca Shakir
- Georgios Ntentas
- Sander Roberti
- Marianne Aznar
- Katinka John
- Johanna Ramroth
- Cécile P.M. Janus
- Augustinus Krol
- Judith Roesink
- Richard W.M. van der Maazen
- Josée M. Zijlstra
- Sarah Darby
- Berthe M. P. Aleman
- Flora E. van Leeuwen
- David Cutter
- Michael Schaapveld
View full abstract at Hemasphere…
72: Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study
Authors:
- Sára Rossetti
- Sidsel Jacobsen Juul
- Frank Eriksson
- Peder Emil Warming
- Charlotte Glinge
- Tarec Christoffer El-Galaly
- Jacob Haaber Christensen
- Peter Kamper
- Peter de Nully Brown
- Maja Vestmø Maraldo
- Jacob Tfelt-Hansen
- Martin Hutchings
View full abstract at Hemasphere…
160: My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients.
Authors:
- Gajan Kailainathan
- Janlyn Falconer
- Amy Baker
- Nicole Wong Doo
- Judith Trotman
View full abstract at Hemasphere…
98: Pneumococcal infection in splenectomised Hodgkin lymphoma patients: Do they pose a problem today and what is the best long-term strategy?
Authors:
- Magnus Björkholm
- Caroline E. Weibull
- Paul Dickman
View full abstract at Hemasphere…
108: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
Authors:
- Rebecca Shakir
- Victoria Butterworth
- Georgios Ntentas
- Johanna Ramroth
- David Cutter
View full abstract at Hemasphere…
106: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
Authors:
- Nele Stadtbaeumer
- Axel Mayer
- Peter Borchmann
View full abstract at Hemasphere…
109: PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians
Authors:
- Sergio Ramos-Cillan
- Eva Castillo
- Miriam Riesco
- Antonio Herroro
- Adriana Pascual
- Alberto Lopez-Garcia
- Maria Angeles Perez
- Daniel Morillo
- ALham Askari
- Elena Prieto
- Pilar LLamas
- Javier Becares
- Carla Barriocanal
- Marta Del Olmo
- Jorge Short
- Javier Arcos
- Raul Córdoba
View full abstract at Hemasphere…
64: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment
Authors:
- Adinda Mieras
- Annelies Nijdam
- Berthe M. P. Aleman
- Laurien Daniels
- Eva de Jongh
- Cécile P.M. Janus
- Stijn Krol
- Bastiaan D.P. Ta
- Francisca Ong
- Dick Johan van Spronsen
- Ward Posthuma
- Wouter J. Plattel
- Rimke Oostvogels
- Karijn Verschueren
- Josée M. Zijlstra
- Flora E. van Leeuwen
View full abstract at Hemasphere…
118: Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival
Authors:
- Joachim Baech
- Lasse Hjort Jakobsen
- Tarec Christoffer El-Galaly
- Daniel Molin
- Ingrid Glimelius
- Joshua P. Entrop
- Michael J. Crowther
- Karin E. Smedby
- Sandra Eloranta
- Caroline E. Weibull
View full abstract at Hemasphere…

Older & Frail Patients

147: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.
Authors:
- Ninja Övergaard
- Kjersti Lia
- Peter Asdahl
- Per Wikman
- Ingrid Glimelius
- Ingemar Lagerlöf
- Ann-Sofie Johansson
- Lotta Hansson
- Gunilla Enblad
- Johan Linderoth
- Christina Goldkuhl
- Alexander Fosså
- Peter Kamper
- Daniel Molin
View full abstract at Hemasphere…
Abstract Talk in “Older and Frail Patients”
127: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
Authors:
- Jenica Upshaw
- Jason Nelson
- Angie Mae Rodday
- Anita Kumar
- Andreas Klein
- Marvin Konstam
- John Wong
- Iris Jaffe
- Bonnie Ky
- Jonathan W. Friedberg
- Matthew Mauer
- David Kent
- Susan K. Parsons
View full abstract at Hemasphere…
Abstract Talk in “Older and Frail Patients”
71: Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry
Authors:
- Lilian Goveia
- Nelson Castro
- Carmino de Souza
- Carolina Colaço Villarim
- Fabiola Traina
- Carlos Sergio Chiattone
- Monica Praxedes
- Cristiana Solza
- Leila Perobelli
- Otavio Baiocchi
- Rafael Gaiolla
- Carla Boquimpani
- Valeria Buccheri
- Caroline Bonamin Sola
- Roberta Oliveira de Paula e Silva
- Ana Carolina Ribas
- Giovana Steffenello
- Katia Pagnano
- Andrea Soares
- Samuel Souza Medina
- Talita Silveira
- Karin Zattar Cecyn
- Leonardo Carvalho Palma
- Mariana de Oliveira Marques
- Nelson Spector
- Irene Biasoli
View full abstract at Hemasphere…
Abstract Talk in “Older and Frail Patients”
184: Epidemiology and results of the first line therapy of HIV-related Hodgkin Lymphoma: Russian retrospective multicenter study
Authors:
- Andrey Chekalov
- Marina Popova
- Ivan Tsygankov
- Yuliya Rogacheva
- Nikita Volkov
- Anastasia Beynarovich
- Kirill Lepik
- Marina Demchenkova
- Marina Grigorieva
- Tatiana Schneider
- Yuliya Kopeikina
- Natalia Medvedeva
- Ilya Zyuzgin
- Elena Pavlyuchenko
- Alexander Levanov
- Alexander Myasnikov
- Natalia Mikhailova
- Vadim Baykov
- Alexander Kulagin
View full abstract at Hemasphere…

Immunotherapy

59: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
Authors:
- Ryan C. Lynch
- Stefan Alig
- Chaitra S. Ujjani
- Christina Poh
- Edus H. Warren
- Stephen D. Smith
- Mazyar Shadman
- Andrei Shustov
- Brian Till
- Vikram M. Raghunathan
- Yolanda Tseng
- Hilary Coye
- Megan Shelby
- Susan Ottemiller
- Sarith Keo
- Kaitlin Verni
- Hongyan Du
- Jackie Vandermeer
- Ashley Gaston
- Heather Rasmussen
- Avanti Gulhane
- Delphine L. Chen
- Paul Martin
- Edmond Marzbani
- Jenna Voutsinas
- Ash A. Alizadeh
- Ajay K. Gopal
View full abstract at Hemasphere…
Abstract Talk in “Immunotherapy”
174: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Authors:
- Peter Borchmann
- Nathalie A. Johnson
- David Lavie
- Gareth Gregory
- Alex F. Herrera
- Leonard Minuk
- Vladan Vucinic
- Philippe Armand
- Abraham Avigdor
- Robin Gasiorowski
- Yair Herishanu
- Colm Keane
- John Kuruvilla
- John Palcza
- Pallavi Pillai
- Akash Nahar
- John Timmerman
View full abstract at Hemasphere…
Abstract Talk in “Immunotherapy”
129: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
Authors:
- Zhiyuan Shi
- Verena Kern
- Max Freihammer
- Jennifer Schitz
- Sven Borchmann
View full abstract at Hemasphere…
167: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
Authors:
- Liudmila Fedorova
- Kirill Lepik
- Natalia Mikhailova
- Elena Kondakova
- Yaroslava Komarova
- Polina Kotselyabina
- Evgenia Borzenkova
- Vadim Baykov
- Ivan Moiseev
- Alexander Kulagin
View full abstract at Hemasphere…
166: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
Authors:
- Liudmila Fedorova
- Kirill Lepik
- Natalia Mikhailova
- Elena Kondakova
- Yaroslava Komarova
- Polina Kotselyabina
- Evgenia Borzenkova
- Vadim Baykov
- Ivan Moiseev
- Alexander Kulagin
View full abstract at Hemasphere…
189: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
Authors:
- Paul J. Bröckelmann
- Helen Kaul
- Michael Fuchs
- Carsten Kobe
- Christian Baues
- Peter Borchmann
- Andreas Engert
View full abstract at Hemasphere…
179: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
Authors:
- John Timmerman
- David Lavie
- Nathalie A. Johnson
- Abraham Avigdor
- Peter Borchmann
- Charalambos Andreadis
- Ali Bazargan
- Gareth Gregory
- Colm Keane
- Inna Tzoran
- Vladan Vucinic
- Pier Luigi Zinzani
- Hong Zhang
- Pallavi Pillai
- Akash Nahar
- Alex F. Herrera
View full abstract at Hemasphere…

Advanced Stages

134: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
Authors:
- Arjan Diepstra
- Lydia Visser
- Catherine Fortpied
- Walter Noordzij
- Annika Loft
- Anne Arens
- Anna Sureda-Balari
- Susana Carvalho
- Andrej Vranovský
- Ward Sents
- Emanuel Buhrer
- Wouter J. Plattel
- Martin Hutchings
View full abstract at Hemasphere…
Abstract Talk in “Advanced Stages”
193: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
Authors:
- Peter Borchmann
- Alden Moccia
- Richard Greil
- Mark Herzberg
- Alexander Fosså
- Andreas Hüttmann
- Felix Keil
- Judith Dierlamm
- Valdete Schaub
- Mathias Hänel
- Urban Novak
- Julia Meissner
- Johannes Hellmuth
- Stephan Mathas
- Josée M. Zijlstra
- Andreas Viardot
- Bernd Hertenstein
- Sonja Martin
- Pratush Giri
- Stefanie Kreissl
- Michael Fuchs
- Gundolf Schneider
- Andreas Rosenwald
- Wolfram Klapper
- Hans Theodor Eich
- Christian Baues
- Michael Hallek
- Carsten Kobe
- Volker Diehl
- Andreas Engert
View full abstract at Hemasphere…
Abstract Talk in “Advanced Stages”
92: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
Authors:
- Hasmukh Jain
- Ajay Singh
- Manju Sengar
- Thomas Eipe
- Hiral Mehta
- Bhausaheb Bagal
- Jayashree Thorat
- Lingaraj Nayak
- Neha Sharma
View full abstract at Hemasphere…
80: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
Authors:
- Simonetta Viviani
- Chiara Pavoni
- Sally F. Barrington
- Luca Guerra
- Heiko Schöder
- Peter Johnson
- Amy A. Kirkwood
- Deborah M. Stephens
- Jonathan W. Friedberg
- Stephane Chauvie
- Michael V. Knopp
- Massimo Federico
- Gunilla Enblad
- Paolo Corradini
- Andrea Gallamini
- Alessandro Rambaldi
- Corrado Tarella
View full abstract at Hemasphere…
66: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
Authors:
- Andrea Visentin
- Alessandro Cellini
- Chiara Adele Cavarretta
- Leila Romano Gargarella
- Francesco Angotzi
- Valeria Ruocco
- Simone Zoletto
- Stefano Pravato
- Marco Pizzi
- Federica Vianello
- Filippo Crimì
- Stefania Vio
- Michele Gregianin
- Livio Trentin
View full abstract at Hemasphere…
135: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
Authors:
- Chiara Rusconi
- Benedetta Puccini
- Carlo Visco
- Francesca Ricci
- Alessandro Re
- Vittorio R. Zilioli
- Caterina Zerbi
- Stefan Hohaus
- Federico Mazzon
- Manuel Ciceri
- Anna Guidetti
- Vincenzo Marasco
- Luigi Rigacci
View full abstract at Hemasphere…
178: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
Authors:
- Elena Dorokhina
- T.N. Moiseeva
- A.M. Kovrigina
- Irirna Shupletsova
- L.S. Al-Radi
- Yu. A. Chabaeva
- Ya.K. Mangasarova
View full abstract at Hemasphere…
57: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
Authors:
- Conrad-Amadeus Voltin
- Stefanie Kreissl
- Helen Kaul
- Ina Bühnen
- Jasmin Mettler
- Thomas Pabst
- Dennis A. Eichenauer
- Michael Fuchs
- Volker Diehl
- Markus Dietlein
- Andreas Engert
- Peter Borchmann
- Carsten Kobe
View full abstract at Hemasphere…
99: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
Authors:
- Martin Hutchings
- Stephen M. Ansell
- Joseph M. Connors
- Won Seog Kim
- Andrea Gallamini
- Radhakrishnan Ramchandren
- Jonathan W. Friedberg
- Ranjana Advani
- Andrew M. Evens
- Piotr Smolewski
- Kerry J. Savage
- Nancy L. Bartlett
- Hyeon-Seok Eom
- Jeremy S. Abramson
- Cassie Dong
- Frank Campana
- Keenan Fenton
- Markus Puhlmann
- David J. Straus
- John Radford
View full abstract at Hemasphere…
121: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
Authors:
- Susan K. Parsons
- Angie Mae Rodday
- Jonathan W. Friedberg
- Andrea Gallamini
- Eliza Hawkes
- David Hodgson
- Peter Johnson
- Brian Link
- Matthew Maurer
- Jason Nelson
- Kerry J. Savage
- Jenica Upshaw
- Pier Luigi Zinzani
- Andrew M. Evens
View full abstract at Hemasphere…
188: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin ́s Lymphoma: Which score to choose
Authors:
- Cátia Almeida
- Rita Costa e Sousa
- Adriana Roque
- Maria Carolina Afonso
- Dulcelena Neves
- Raquel Guilherme
- Lenka Ruzickova
- José Pedro Carda
- Catarina Geraldes
- Marília Gomes
View full abstract at Hemasphere…
131: Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience
Authors:
- Francesca Pierdomenico
- Raquel Marques
- Dulcelena Neves
- João Gaião Santos
- Christopher Saunders
- Rita Pinho Peixeiro
- Marta Henriques
- Ana Tome
- Daniela Alves
- Margarida Badior
- Tathiane Lopes
- Sonia Leocadio
- Marília Gomes
- Alexandra Monteiro
- Rita Coutinho
- Ana Luisa Pinto
- Anabela Neves
- João Paulo Fernandes
- Maria Gomes da Silva
View full abstract at Hemasphere…
103: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
Authors:
- Korin Laura
- Victoria Otero
- Carolina Mahuad
- Enriqueta Martinez
- Fernando Warley
- Hernan García Rivello
- Nancy Cristaldo
- Dana Kohan
- Gonzalo Garate
- Maria de los Angeles Vicente Reparaz
- Maria Florencia Aizpurua
- Erica Rojas Bilbao
- Susana Cerana
- María Eugenia Funes
- Iliana Plaza
- Cecilia Foncuberta
- Anahi Vijnovich Baron
- Santiago Cranco
- Adriana Vitriu
- Mariela Gomez
- Justina Lavalle
- Claudia Casali
- Manuela Clavijo
- Luciana Melillo
- Maria Cecilia Cabral Lorenzo
- Augusto Miroli
- Laura Fishman
- Maximi
View full abstract at Hemasphere…
186: Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
Authors:
- Rita Costa e Sousa
- Cátia Almeida
- Adriana Roque
- Maria Carolina Afonso
- Dulcelena Neves
- Raquel Guilherme
- Lenka Ruzickova
- José Pedro Carda
- Catarina Geraldes
- Marília Gomes
View full abstract at Hemasphere…
94: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
Authors:
- Anna Santarsieri
- Katherine Sturgess
- Pauline Brice
- Tobias F. Menne
- Wendy Osborne
- Thomas Creasey
- Kirit M. Ardeshna
- Sarah Behan
- Kaljit Bhuller
- Stephen Booth
- Nikesh Chavda
- Graham P. Collins
- Dominic Culligan
- Kate Cwynarski
- Andrew Davies
- David Dutton
- Michelle Furtado
- Eve Gallop-Evans
- Andrew Hodson
- David Hopkins
- Hannah Hsu
- Sunil Iyengar
- Stephen G. Jones
- Kim Linton
- Oliver Lomas
- Nicolas Martinez-Calle
- Abhinav Mathur
- Pamela McKay
- Sateesh K. Nagumantry
- Deidre O'Mahony
- Beth Phillips
- Neil
View full abstract at Hemasphere…
152: Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
Authors:
- Ida Hude Dragičević
- Sandra Bašić-Kinda
- Dino Dujmović
- Ivo Radman
- Barbara Dreta
- Sandra Dotlić
- Lea Galunić-Bilić
- Margareta Dobrenić
- Marko Kralik
- Pavle Rončević
- Igor Aurer
View full abstract at Hemasphere…
187: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma.
Authors:
- Michal Taszner
- Grzegorz Romanowicz
- Wanda Knopińska-Posłuszny
- Janusz Hałka
- Edyta Subocz
- Bogdan Małkowski
- Jan Maciej Zaucha
View full abstract at Hemasphere…
70: Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry
Authors:
- Irene Biasoli
- Nelson Castro
- Carolina Colaço Villarim
- Fabiola Traina
- Carlos Sergio Chiattone
- Monica Praxedes
- Cristiana Solza
- Leila Perobelli
- Otavio Baiocchi
- Rafael Gaiolla
- Carla Boquimpani
- Valeria Buccheri
- Caroline Bonamin Sola
- Roberta Oliveira de Paula e Silva
- Ana Carolina Ribas
- Giovana Steffenello
- Katia Pagnano
- Andrea Soares
- Samuel Souza Medina
- Talita Silveira
- Karin Zattar Cecyn
- Lilian Goveia
- Leonardo Carvalho Palma
- Mariana de Oliveira Marques
- Carmino de Souza
- Nelson Spector
View full abstract at Hemasphere…
177: Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
Authors:
- Elena Dorokhina
- T.N. Moiseeva
- A.M. Kovrigina
- Irirna Shupletsova
- L.S. Al-Radi
- Yu. A. Chabaeva
- Ya.K. Mangasarova
View full abstract at Hemasphere…

Genomics, Biology & Microenvironment

132: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
Authors:
- Kristiina Karihtala
- Suvi-Katri Leivonen
- Marja-Liisa Karjalainen-Lindsberg
- Arne Östman
- Teijo Pellinen
- Sirpa Leppä
View full abstract at Hemasphere…
Abstract Talk in “Genomics, Biology and Microenvironment”
115: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
Authors:
- Arjan Diepstra
- Ilja M. Nolte
- Anke van den Berg
- Lynn I. Levin
- Otoniel Martínez-Maza
View full abstract at Hemasphere…
Abstract Talk in “Genomics, Biology and Microenvironment”
159: Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
Authors:
- Julia Paczkowska
- Ming Tang
- Kyle T. Wright
- Li Song
- Vignesh Shanmugam
- Kelsey Luu
- Emma L. Welsh
- Fathima Zumla Cader
- Elisa Mandato
- Jing Ouyang
- Gali Bai
- Lee Lawton
- Scott Rodig
- X Shirley Liu
- Margaret A. Shipp
View full abstract at Hemasphere…
Abstract Talk in “Genomics, Biology and Microenvironment”
191: Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?
Authors:
- Radhia M'kacher
- Steffen Junker
- Bruno Colicchio
- Wala Najar
- Justyna Mika
- Alain Dieterlen
- Joanna Polanska
- Philippe Voisin
- Eric Jeandidier
- Patrice Carde
View full abstract at Hemasphere…
172: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
Authors:
- Alessandra Romano
- Claudio Cerchione
- Gabriella Santuccio
- Marialudovica Le Moli
- Annalisa Chiarenza
- Amalia Figuera
- Giovanna Motta
- L. Caruso
- Sofia Lanza
- A. Petronaci
- S. Poidomani
- Massimo Ippolito
- Francesco Di Raimondo
View full abstract at Hemasphere…
101: CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
Authors:
- Johanna Veldman
- Jessica Rodrigues Plaça
- Lauren Chong
- Martijn Terpstra
- Mirjam Mastik
- Léon C. van Kempen
- Tomohiro Aoki
- Christian Steidl
- Anke van den Berg
- Lydia Visser
- Arjan Diepstra
View full abstract at Hemasphere…
139: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
Authors:
- Tom A. Mulder
- Maria L. Andersson
- Lucia Peña-Pérez
- Kia Heimersson
- Ioanna Xagoraris
- Björn E. Wahlin
- Robert Månsson
- Lotta Hansson
- Georgios Z. Rassidakis
- Marzia Palma
View full abstract at Hemasphere…
155: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
Authors:
- Irirna Shupletsova
- Alla Kovrigina
- Elena Dorokhina
- Tatyana Moiseeva
View full abstract at Hemasphere…
82: Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
Authors:
- Ilaria Romano
- Benedetta Puccini
- Elisabetta Abenavoli
- Leonardo Signori
- Marianna Palazzo
- Manuel Ciceri
- Benedetta Sordi
- Valentina Berti
- Michela Zizza
- Fabiana Pancani
- Luca Nassi
- Alessandro Maria Vannucchi
View full abstract at Hemasphere…
93: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
Authors:
- Annika L. Kilian
- Anna Lollies
- Marc A. Weniger
- Ralf Küppers
View full abstract at Hemasphere…
125: Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma
Authors:
- Jan Grohmann
- Alexandra Kredatusova
- Jana Navratilova
- Veronika Hanackova
- Helena Urbankova
- Vit Prochazka
- Tomas Papajik
View full abstract at Hemasphere…
137: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
Authors:
- Laman Mammadova
- Jan-Michel Heger
- Julia Mattlener
- Sophia Sobesky
- Melita Cirillo
- Paul J. Bröckelmann
- Janine Altmüller
- Elisabeth Kirst
- Stefanie Kreissl
- Mia Lohmann
- Peter Nürnberg
- Andreas Engert
- Peter Borchmann
- Bastian von Tresckow
- Sven Borchmann
View full abstract at Hemasphere…
117: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
Authors:
- Berit Müller-Meinhard
- Sarah Reinke
- Nicole Seifert
- Andreas Engert
- Paul J. Bröckelmann
- Michael Altenbuchinger
- Wolfram Klapper
View full abstract at Hemasphere…
102: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
Authors:
- Johanna Grund
- Sarah Reinke
- Annette Plütschow
- Bastian von Tresckow
- Peter Borchmann
- Andreas Engert
- Paul J. Bröckelmann
- Wolfram Klapper
View full abstract at Hemasphere…
173: LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells
Authors:
- Annika Wadel
- Leonie Jaster
- Martin S. Staege
View full abstract at Hemasphere…
74: Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
Authors:
- Laura Korin
- Santiago Cranco
- Lucia Fuente
- Adriana Vitriu
- Paola Ochoa
- Evelina Babuin
- Olivia Gelo
- Luis Ayala
- Andrea Novoa
- Paula Tempra
- Maria Belen Venegas
- Anahi Vijnovich Baron
- Norma Tartas
- Rosario Custidiano
- Cecilia Foncuberta
- Julio Sanchez Avalos
View full abstract at Hemasphere…
185: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
Authors:
- Alessandra Romano
- Grazia Scandura
- Gabriella Santuccio
- Fabrizio Puglisi
- Daniela Cambria
- Angela Maria Amorini
- Enrico La Spina
- Nunziatina Laura Parrinello
- Cesarina Giallongo
- Daniele Tibullo
- Claudio Cerchione
- Giovanni Martinelli
- Giorgia Simonetti
- Francesco Di Raimondo
View full abstract at Hemasphere…
110: Molecular pathogenesis of Hodgkin lymphoma
Authors:
- Lilian Beeck
- Markus Schneider
- Navid Farsijani
- Bettina Budeus
- Julia Bein
- Hendrik Schaefer
- Sylvia Hartmann
- Martin-Leo Hansmann
- Ralf Küppers
View full abstract at Hemasphere…
161: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
Authors:
- Maciej Szydłowski
- Filip Garbicz
- Ewa Kurtz
- Michał Pawlak
- Patryk Górniak
- Anna Szumera-Ciećkiewicz
- Kamil Sokół
- Monika Kawecka
- Daria Owczarek
- Beata Puton
- Monika Prochorec-Sobieszek
- Daniela Bellarosa
- Michał Kurlapski
- Jan Maciej Zaucha
- Przemysław Juszczyński
View full abstract at Hemasphere…
79: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
Authors:
- Johan Mattsson Ulfstedt
- Eva Freyhult
- Christina Christersson
- Charlott Mörth
- Masood Kamali-Moghaddam
- Anna Eriksson
- Gunilla Enblad
- Daniel Molin
View full abstract at Hemasphere…
138: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
Authors:
- Mia Lohmann
- Iris Buchberger
- Anna Beielstein
- Başak Kaçar
- Julia Mattlener
- Marieke Nill
- Zhiyuan Shi
- Jan-Michel Heger
- Christian Pallasch
- Roland Ullrich
- Sven Borchmann
View full abstract at Hemasphere…
164: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
Authors:
- Vit Prochazka
- Heidi Mocikova
- Alice Sykorova
- Jana Markova
- Marie Lukášová
- Lubica Gaherova
- Alexandra Kredatusova
- Eva Kriegova
- Maria Maco
- Tomas Kozak
- David Belada
- Tomas Papajik
View full abstract at Hemasphere…
112: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
Authors:
- Jonathan Fromm
- Claire Tang
- Kikkeri N. Naresh
View full abstract at Hemasphere…
114: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
Authors:
- Nicole Seifert
- Sarah Reinke
- Johanna Grund
- Berit Müller-Meinhard
- Andreas Engert
- Paul J. Bröckelmann
- Wolfram Klapper
- Michael Altenbuchinger
View full abstract at Hemasphere…
168: Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells
Authors:
- Michał Kurlapski
- Maciej Szydłowski
- Alicja Braczko
- Marika Frańczak
- Maciej Zieliński
- Ryszard Smoleński
- Przemysław Juszczyński
- Jan Maciej Zaucha
View full abstract at Hemasphere…
146: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
Authors:
- Alexia Piperidou
- Eleftherios Zografos
- Theodoros P. Vassilakopoulos
- Maria K. Angelopoulou
- Georgios Hlias
- Vassiliki Pappis
- George Boutsikas
- Maria Dimou
- Kyriaki Petevi
- Alexandros Kanellopoulos
- Marie-Christine Kyrtsonis
- Panayiotis Panayiotidis
View full abstract at Hemasphere…
78: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
Authors:
- Ioanna Xagoraris
- Konstantina Stathopoulou
- Stefanie Renken
- Andreas Lundqvist
- Francois Xavier Claret
- Elias Drakos
- Georgios Z. Rassidakis
View full abstract at Hemasphere…
158: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
Authors:
- Ioanna Xagoraris
- Konstantina Stathopoulou
- Persa Xyderou
- Marzia Palma
- Elias Drakos
- Theodoros P. Vassilakopoulos
- Georgios Z. Rassidakis
View full abstract at Hemasphere…
86: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
Authors:
- Andrea Visentin
- Edoardo Ruggeri
- Federica Frezzato
- Marco Pizzi
- Alessandro Cellini
- Francesco Angotzi
- Chiara Adele Cavarretta
- Valeria Ruocco
- Stefano Pravato
- Filippo Severin
- Monica Facco
- Sabrina Manni
- Francesci Piazza
- Livio Trentin
View full abstract at Hemasphere…
111: Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin lymphoma
Authors:
- Ilia Buhtoiarov
- Brian Hill
- Ilan Kirsch
- Nancy Richter
- Rabi Hanna
View full abstract at Hemasphere…
156: Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells
Authors:
- Patricia Lein
- Charles Gwellem Anchang
- Ines Volkmer
- Martin S. Staege
View full abstract at Hemasphere…
77: Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma
Authors:
- Ilja Kalashnikov
- Rachel Kositsky
- Marja-Liisa Karjalainen-Lindsberg
- Johannes Dunkel
- Annika Pasanen
- Cassandra Love
- Clay Parker
- Sarah Ondrejka
- Eric Hsi
- Ridas Juskevicius
- Andrew Evans
- Andrew G. Evans
- Magdalena Czader
- Lin Wang
- Mina Xu
- Nathan Paulson
- Mette Ølgod Pedersen
- Anne Ortved Gang
- Jean Koff
- Chad McCall
- Yaso Natkunam
- Abner Louissaint
- Ong Shin Yeu
- Raju Pillai
- Jennifer Chapman
- Catalina Amador
- Amy Chadburn
- Rashmi Goswami
- Amir Behdad
- Payal Sojitra
- Eric Tse
- Naresh Kikkeri
- Kikkeri
View full abstract at Hemasphere…

Relapsed/Refractory

163: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
Authors:
- Anna Sureda-Balari
- M. José Terol
- Eva Domingo-Domènech
- Ana Pilar González Rodriguez
- Francisca Hernández Mohedo
- Javier Núñez Céspedes
- Fátima de la Cruz Vicente
- Carmen Martínez Muñoz
- M. Elena Amutio Díaz
- Raul Córdoba
- Antonia Rodríguez Izquierdo
- Samuel Romero Domínguez
- Javier Briones Meijide
- Richard Greil
- Miriam Moreno Velázquez
- Araceli Rubio
- Mariana Bastos Oteiro
- Pilar Gómez
- Irit Avivi
- María Casanova
- Raquel Del Campo García
- Victor Noriega
- José Javier Sánchez Blanco
View full abstract at Hemasphere…
Abstract Talk in “Relapsed / Refractory HL”
149: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
Authors:
- Alison J. Moskowitz
- Gunjan Shah
- Heiko Schöder
- Nivetha Ganesan
- Helen Hancock
- Theresa Davey
- Leslie Perez
- Samia Sohail
- Alayna Santarosa
- Charisse Capadona
- Brittney Munayirji
- Anita Kumar
- Oscar Lahoud
- Connie Batlevi
- Paul Hamlin
- David J. Straus
- Colette Owens
- Philip Caron
- Andrew Intlekofer
- Audrey Hamilton
- Steven Horwitz
- Lorenzo Falchi
- William Johnson
- Lia Palomba
- Ariela Noy
- Matthew Matasar
- Georgios Pongas
- Gilles Salles
- Santosha Vardhana
- Beatriz Wills Sanin
- Joachim Yahalom
- Ahmet Dogan
View full abstract at Hemasphere…
Abstract Talk in “Relapsed / Refractory HL”
181: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
Authors:
- Catherine Diefenbach
- Opeyemi Jegede
- Richard Ambinder
- Jonathon Cohen
- Michael Robertson
- Kevin David
- Ranjana Advani
- Timothy Fenske
- Stefan Barta
- Neil Palmisiano
- Jakub Svoboda
- David Morgan
- Reem Karmali
- Brad Kahl
- Stephen M. Ansell
View full abstract at Hemasphere…
Abstract Talk in “Relapsed / Refractory HL”
165: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin's lymphoma.
Authors:
- Ya.K. Mangasarova
- T.N. Moiseeva
- L.S. Al-Radi
- O.V. Margolin
- L.G. Gorenkova
- E.S. Nesterova
- M.O. Bagova
- E.A. Fastova
- R.R. Abdurashidova
- Z.T. Sarakaeva
- Elena Dorokhina
- S.K. Kravchenko
- A.U. Magomedova
- E.E. Zvonkov
View full abstract at Hemasphere…
91: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
Authors:
- Harsh Shah
- Victoria Vardell
- Erin Zacholski
- Amanda Fegley
- Kalub Fedak
- Suchitra Sundaram
- Sridevi Rajeeve
- Gaurav Goyal
- Haris Hatic
- Pallawi Torka
- Sheeba Ba Aqeel
- Azra Borogovac
- Kira MacDougall
- Shalin Kothari
- Anna Kress
- Dipenkumar Modi
- Elizabeth Travers
- Nitin Chilakamarri
- Elizabeth Brem
- Deborah M. Stephens
- Boyu Hu
- Lindsey Fitzgerlad
- Charlotte Wagner
- Daniel Ermann
View full abstract at Hemasphere…
190: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
Authors:
- Serageldin Kamel
- Lucia Martiniova
- Eslam Aboismail
- Joo Schmidt
- Sairah Ahmed
- Ranjit Nair
- Raphael E. Steiner
- Michael L. Wang
- Sarita Soebianto
- Gregory Ravizzini
- Tinsu Pan
- Hun Ju Lee
View full abstract at Hemasphere…
122: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
Authors:
- Jozef Michalka
- Jana Marková
- Ľubica Gahérová
- Mária Maco
- Vít Procházka
- Jan Kořen
- Alice Sýkorová
- Pavla Štěpánková
- Kateřina Steinerová
- Lekaa Mohammad
- Juraj Ďuraš
- Barbora Velacková
- Tomáš Doležal
- Kateřina Benešová
- Marie Lukášová
- Andrea Janíková
- Zdeněk Král
- Heidi Móciková
View full abstract at Hemasphere…
145: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
Authors:
- Chiara Rusconi
- Francesca Ricci
- Vittorio R. Zilioli
- Vincenzo Marasco
- Eleonora Calabretta
- Anna Guidetti
- Cristina Muzi
- Federico Mazzon
- Margherita Smania
- Martina Sollini
- Erika Meli
- Marcello Rodari
- Emanuele Ravano
- Roberto Cairoli
- Paolo Corradini
- Armando Santoro
View full abstract at Hemasphere…
140: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
Authors:
- Axel Erenmalm
- Johan Linderoth
View full abstract at Hemasphere…
105: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
Authors:
- Julia Driessen
- Fer De Wit
- Alex F. Herrera
- Pier Luigi Zinzani
- Ann S. LaCasce
- Peter D. Cole
- Craig H. Moskowitz
- Ramón García Sanz
- Michael Fuchs
- Horst Müller
- Peter Borchmann
- Armando Santoro
- Heiko Schöder
- Josée M. Zijlstra
- Barbara A. Hutten
- Alison J. Moskowitz
- Marie José Kersten
View full abstract at Hemasphere…
183: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
Authors:
- Eleonora Calabretta
- Martina Di Trani
- Martina Sollini
- Francesca Ricci
- Francesco Corrado
- Vanessa Cristaldi
- Stefanos Bonovas
- Fabrizio Marino
- Rita Mazza
- Lodovico Terzi di Bergamo
- Alessio Bruscaggin
- Maria Cristina Pirosa
- Stefania Bramanti
- Arturo Chiti
- Armando Santoro
- Davide Rossi
- Carmelo Carlo-Stella
View full abstract at Hemasphere…
180: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
Authors:
- Hannah Moatti
- Marie-Céleste Laroque
- Loïc Renaud
- Odonchimeg Ravdan
- Charlotte Schmidt-Hieber
- Isabelle Madelaine
- Roberta Di Blasi
- Catherine Thieblemont
- Pauline Brice
View full abstract at Hemasphere…
88: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
Authors:
- Simonetta Viviani
- Anna Vanazzi
- Samuele Frassoni
- Chiara Rusconi
- Andrea Rossi
- Alessandra Romano
- Caterina Patti
- Corrado Schiavotto
- Roberto Sorasio
- Vincenzo Marasco
- Laura Lissandrini
- Davide Rapezzi
- Daniela Gottardi
- Federica Cocito
- Antonino Mulè
- Guido Gini
- Roberta Zanotti
- Alessandro Rambaldi
- Vincenzo Bagnardi
- Corrado Tarella
View full abstract at Hemasphere…
143: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
Authors:
- Swetha Kambhampati
- Matthew Mei
- Lu Chen
- Sandrine Puvurel
- Robert Chen
- Leslie Popplewell
- Liana Nikolaenko
- Lacolle Peters
- Saro Armenian
- Larry Kwak
- Steven T. Rosen
- Stephen Forman
- Alex F. Herrera
View full abstract at Hemasphere…
162: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
Authors:
- Matthew Mei
- Joycelynne Palmer
- Kami Maddocks
- Peter Martin
- Ni-Chun Tsai
- Eileen Smith
- Leslie Popplewell
- Saro Armenian
- Geoffrey Shouse
- Robert Chen
- Larry Kwak
- Steven T. Rosen
- Stephen Forman
- David Bond
- Alex F. Herrera
View full abstract at Hemasphere…
154: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
Authors:
- Caterina Zerbi
- Tanja Lazic
- Roberta Sciarra
- Caterina Cristinelli
- Alessandro Mazzacane
- Federico Carpi
- Virginia Valeria Ferretti
- Giulia Gambini
- Maurizio Bonfichi
- Luca Arcaini
- Manuel Gotti
View full abstract at Hemasphere…
126: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
Authors:
- Theodoros P. Vassilakopoulos
- Athanasios Liaskas
- Giuliana Rizzuto
- Argyrios Symeonidis
- Marzia Palma
- Maria K. Angelopoulou
- Chara Giatra
- Flora Kondopidou
- Maria Dimou
- Alberto Musseti
- Ioanna Xagoraris
- Marina Siakantaris
- Evgenia Verigou
- Fotios Panitsas
- John Asimakopoulos
- Maria Arapaki
- Chrysovalantou Chatzidimitriou
- Marina Belia
- Sotirios Sachanas
- Penelope Korkolopoulou
- Antonello Cabras
- Eleni Variamis
- Panayiotis Panayiotidis
- Maria Bakiri
- Themistoklis Karmiris
- Georgios Z. Rassidakis
- Paolo C
View full abstract at Hemasphere…

Pediatric HL

116: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL
Authors:
- Jamie E. Flerlage
- Suzi Birz
- Sharon M. Castellino
- Burton Appel
- Brian Furner
- Luca Graglia
- Tara O. Henderson
- David Hodgson
- Bradford S. Hoppe
- Justine Kahn
- Frank G. Keller
- Sandy Kessel
- Chen Li
- Mei Li
- John Lucas
- Kathleen McCarten
- Monika Metzger
- Sarah Milgrom
- Susan K. Parsons
- Qinglin Pei
- Yue Wu
- Yiwang Zhou
- Michael Watkins
- Sam Volchenbaum
- Kara M. Kelly
View full abstract at Hemasphere…
76: Case series of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Tanzania. A common entity in East Africa?
Authors:
- Atukuzwe Kahakwa
- Elifuraha Mkwizu
- Alex Mremi
- Priscus Mapendo
- Oliver Henke
View full abstract at Hemasphere…
171: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study
Authors:
- Luciana Vinti
- Stephen Daw
- Constantino Sabado Alvarez
- Franca Fagioli
- Auke Beishuizen
- Gerard Michel
- Maria Luisa Moleti
- Michaela Cepelova
- Anne Thorwarth
- Charlotte Rigaud
- Diego Plaza Lopez de Sabando
- Judith Landman Parker
- Ying Zhu
- Pallavi Pillai
- Akash Nahar
- Christine Mauz-Koerholz
View full abstract at Hemasphere…
144: Staging of Lung Lesions Survey Demonstrates Continued Need for Harmonization
Authors:
- Jennifer Seelisch
- Sue C. Kaste
- Kara M. Kelly
- Lars Kurch
- Michael P. Link
- Christine Mauz-Koerholz
- Kathleen McCarten
- Angela Punnett
- Dietrich Stroevesandt
- Jamie E. Flerlage
View full abstract at Hemasphere…
96: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
Authors:
- Sharon M. Castellino
- Qinglin Pei
- Susan K. Parsons
- David Hodgson
- Kathleen McCarten
- Terzah Horton
- Steve Cho
- Yue Wu
- Angela Punnett
- Hema Dave
- Tara O. Henderson
- Bradford S. Hoppe
- Ann-Marie Charpentier
- Frank G. Keller
- Kara M. Kelly
View full abstract at Hemasphere…

Radiotherapy

148: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients.
Authors:
- Christina Goldkuhl
- Alexandru Dasu
- Anna Bäck
- Gunilla Enblad
- Ingrid Glimelius
- Annika Hall
- Lotta Hansson
- Urban Jerlström
- Ann-Sofie Johansson
- Jenny Kahlmeter-Brandell
- Johan Linderoth
- Marzia Palma
- Hillevi Rylander
- Marika Enmark
- Daniel Molin
View full abstract at Hemasphere…
113: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
Authors:
- Michael Oertel
- Dominik Hering
- Nina Nacke
- Christopher Kittel
- Kai Kröger
- Jan Kriz
- Michael Fuchs
- Christian Baues
- Dirk Vordermark
- Rita Engenhart-Cabillic
- Klaus Herfarth
- Peter Lukas
- Heinz Schmidberger
- Simone Marnitz
- Peter Borchmann
- Andreas Engert
- Uwe Haverkamp
- Hans Theodor Eich
View full abstract at Hemasphere…
55: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
Authors:
- Michael Oertel
- Dominik Hering
- Nina Nacke
- Christopher Kittel
- Kai Kröger
- Jan Kriz
- Michael Fuchs
- Christian Baues
- Dirk Vordermark
- Rita Engenhart-Cabillic
- Klaus Herfarth
- Peter Lukas
- Heinz Schmidberger
- Simone Marnitz
- Peter Borchmann
- Andreas Engert
- Uwe Haverkamp
- Hans Theodor Eich
View full abstract at Hemasphere…
83: Long-term outcomes of bulky classic Hodgkin lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases
Authors:
- Jowon Laura Kim
- Diego Villa
- R. Petter Tonseth
- Alina S. Gerrie
- Don Wilson
- Francois Benard
- Chris Venner
- Brian Skinnider
- Pedro Farinha
- Graham W. Slack
- David W. Scott
- Joseph M. Connors
- Laurie H. Sehn
- Kerry J. Savage
View full abstract at Hemasphere…
85: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
Authors:
- David Jones
- Rebecca Shakir
- Paolo Candio
- Johanna Ramroth
- Jane Wolstenholme
- Alastair Gray
- David Cutter
- Georgios Ntentas
View full abstract at Hemasphere…
89: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin´s lymphoma.
Authors:
- Johan Linderoth
- Eva Freyhult
- Ellinor Andreasson
- Ann-sofie Johansson
- Anne Andersson
- Ingrid Glimelius
- Gunilla Enblad
- Daniel Molin
View full abstract at Hemasphere…
54: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
Authors:
- Michael Oertel
- Dominik Hering
- Christopher Kittel
- Nina Nacke
- Kai Kröger
- Jan Kriz
- Michael Fuchs
- Christian Baues
- Dirk Vordermark
- Rita Engenhart-Cabillic
- Klaus Herfarth
- Peter Lukas
- Heinz Schmidberger
- Simone Marnitz
- Peter Borchmann
- Uwe Haverkamp
- Andreas Engert
- Hans Theodor Eich
View full abstract at Hemasphere…

ISHL12 Abstracts

136: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

124: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.

63: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

104: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma

142: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial

150: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma.

169: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

58: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

182: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.

133: A pilot of lung cancer screening for survivors of Hodgkin lymphoma

157: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)

95: Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients

81: Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?

100: First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands

130: Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma

107: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma

72: Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study

160: My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients.

98: Pneumococcal infection in splenectomised Hodgkin lymphoma patients: Do they pose a problem today and what is the best long-term strategy?

108: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans

106: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors

109: PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians

64: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment

118: Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival

147: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.

127: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma

71: Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

184: Epidemiology and results of the first line therapy of HIV-related Hodgkin Lymphoma: Russian retrospective multicenter study

59: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

174: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

129: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma

167: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment

166: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma

189: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial

179: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

134: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

193: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

92: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.

80: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials

66: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.

135: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi

178: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy

57: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

99: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

121: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium

188: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin ́s Lymphoma: Which score to choose

131: Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience

103: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study

186: Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients

94: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

152: Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)

187: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma.

70: Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry

177: Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)

132: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

115: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

159: Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade

191: Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?

172: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i

101: CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype

139: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.

155: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma

82: Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment

93: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma

125: Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma

137: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma

117: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma

102: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma

173: LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells

74: Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status

185: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma

110: Molecular pathogenesis of Hodgkin lymphoma

161: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma

79: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma

138: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma

164: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group

112: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry

114: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma

168: Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells